Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

Highlights,Viking Therapeutics CEO Brian Lian to present on January 13, 2025, at the J.P. Morgan Healthcare Conference,The ...

A choppy stock market challenges investors to be patient and choose stocks carefully as the Q4 earnings season gets underway.

Vikings head coach Kevin O’Connell has done a terrific job this season. But his future in Minnesota seems far more certain ...

Flores, who previously served as Dolphins head coach from 2019-21, has had interview requests from the Jets and Bears as he ...

"I like Ryan Grigson," NFL super agent Drew Rosenhaus said this week on The Pat McAfee Show. "I've seen him work with the Vikings. Coach Flores is a stud. If someone can get Grigson and Flores as a ...